Research Areas

Muller's team is working to develop a small-molecule Enolase inhibitor for in vivo proof-of-principal, and ultimately, as a clinical candidate for the treatment of cancers which harbor deletions of ENO1. Their goal is to demonstrate the universality of the collateral lethality approach and expand the utility to other passenger deleted genes. The team is using genomic deletions to gain insight into the basic biochemistry and metabolism of human cancer, as well as to utilize this knowledge for imaging purposes.